Truist Financial Corp Sells 4,780 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Truist Financial Corp decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 29.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,570 shares of the medical equipment provider's stock after selling 4,780 shares during the period. Truist Financial Corp's holdings in Lantheus were worth $929,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Quarry LP lifted its position in Lantheus by 51.3% during the second quarter. Quarry LP now owns 1,145 shares of the medical equipment provider's stock valued at $92,000 after purchasing an additional 388 shares during the last quarter. Creative Planning increased its stake in Lantheus by 48.5% in the second quarter. Creative Planning now owns 23,714 shares of the medical equipment provider's stock valued at $1,904,000 after acquiring an additional 7,742 shares during the last quarter. Mackenzie Financial Corp raised its position in Lantheus by 259.2% during the second quarter. Mackenzie Financial Corp now owns 15,571 shares of the medical equipment provider's stock valued at $1,250,000 after purchasing an additional 11,236 shares in the last quarter. Diker Management LLC bought a new stake in Lantheus during the second quarter worth about $419,000. Finally, Alpha DNA Investment Management LLC purchased a new position in shares of Lantheus in the 2nd quarter worth about $412,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on LNTH. B. Riley raised their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Redburn Atlantic assumed coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price on the stock. Truist Financial cut their price target on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. JMP Securities decreased their price objective on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a report on Thursday, August 1st. Finally, Leerink Partners raised their price target on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research report on Thursday, July 11th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Lantheus Trading Down 1.3 %

Shares of NASDAQ:LNTH traded down $1.47 on Monday, hitting $110.72. The company had a trading volume of 416,661 shares, compared to its average volume of 980,834. The firm's 50-day simple moving average is $104.44 and its two-hundred day simple moving average is $89.85. The firm has a market capitalization of $7.67 billion, a price-to-earnings ratio of 16.90 and a beta of 0.50. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million during the quarter, compared to analysts' expectations of $382.12 million. During the same quarter last year, the business earned $1.40 earnings per share. The business's quarterly revenue was up 22.5% on a year-over-year basis. Equities analysts anticipate that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Mary Anne Heino sold 10,481 shares of Lantheus stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the transaction, the director now owns 454,923 shares of the company's stock, valued at $43,445,146.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,981 shares of company stock valued at $2,689,156 over the last ninety days. Company insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.